MX2021002521A - Dimetilaminoazetidinaminas como inhibidores de jak. - Google Patents

Dimetilaminoazetidinaminas como inhibidores de jak.

Info

Publication number
MX2021002521A
MX2021002521A MX2021002521A MX2021002521A MX2021002521A MX 2021002521 A MX2021002521 A MX 2021002521A MX 2021002521 A MX2021002521 A MX 2021002521A MX 2021002521 A MX2021002521 A MX 2021002521A MX 2021002521 A MX2021002521 A MX 2021002521A
Authority
MX
Mexico
Prior art keywords
dimethyl amino
jak inhibitors
amino azetidine
amides
compounds
Prior art date
Application number
MX2021002521A
Other languages
English (en)
Inventor
Daniel D Long
Cameron Smith
Corbin Thompson
Original Assignee
Theravance Biopharma R&D Ip Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Biopharma R&D Ip Llc filed Critical Theravance Biopharma R&D Ip Llc
Publication of MX2021002521A publication Critical patent/MX2021002521A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Abstract

La invención proporciona compuestos de la fórmula (I): (ver Fórmula) (I) donde las variables se definen en la memoria descriptiva, o una sal farmacéuticamente aceptable de estas, que son útiles como inhibidores de la cinasa JAK. La invención también proporciona composiciones farmacéuticas que comprenden dichos compuestos, y métodos de uso de dichos compuestos para tratar las enfermedades respiratorias.
MX2021002521A 2018-09-04 2019-09-03 Dimetilaminoazetidinaminas como inhibidores de jak. MX2021002521A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862726562P 2018-09-04 2018-09-04
PCT/US2019/049276 WO2020051105A1 (en) 2018-09-04 2019-09-03 Dimethyl amino azetidine amides as jak inhibitors

Publications (1)

Publication Number Publication Date
MX2021002521A true MX2021002521A (es) 2021-04-28

Family

ID=67982186

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021002521A MX2021002521A (es) 2018-09-04 2019-09-03 Dimetilaminoazetidinaminas como inhibidores de jak.

Country Status (17)

Country Link
US (3) US10947229B2 (es)
EP (1) EP3837258B1 (es)
JP (2) JP7324836B2 (es)
KR (1) KR20210056381A (es)
CN (1) CN112739697B (es)
AR (1) AR116115A1 (es)
AU (1) AU2019336167A1 (es)
BR (1) BR112021004052A2 (es)
CL (1) CL2021000514A1 (es)
CO (1) CO2021002977A2 (es)
EA (1) EA202190681A1 (es)
IL (1) IL281146B2 (es)
MA (1) MA53229A (es)
MX (1) MX2021002521A (es)
SG (1) SG11202101734RA (es)
TW (1) TWI791886B (es)
WO (1) WO2020051105A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180073687A (ko) 2015-11-03 2018-07-02 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 호흡기 질환의 치료를 위한 jak 키나제 저해제 화합물
EA037748B1 (ru) 2017-03-09 2021-05-18 ТЕРЕВАНС БАЙОФАРМА Ар энд Ди АйПи, ЭлЭлСи Конденсированные имидазо-пиперидиновые ингибиторы jak
TWI808250B (zh) 2018-09-04 2023-07-11 美商施萬生物製藥研發 Ip有限責任公司 用於製備jak抑制劑之方法及其中間體
SG11202101751XA (en) 2018-09-04 2021-03-30 Theravance Biopharma R&D Ip Llc 5 to 7 membered heterocyclic amides as jak inhibitors
KR20210056381A (ko) 2018-09-04 2021-05-18 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 Jak 억제제로서 디메틸 아미노 아제티딘 아마이드
TW202144343A (zh) 2020-03-02 2021-12-01 美商施萬生物製藥研發 Ip有限責任公司 Jak抑制劑化合物之結晶水合物
WO2021226637A1 (en) * 2020-05-08 2021-11-11 Theravance Biopharma R&D Ip, Llc Method of treating a patient infected with a coronavirus with nezulcitinib
US20230021647A1 (en) * 2021-06-21 2023-01-26 Theravance Biopharma R&D Ip, Llc Method of treating a patient infected with a coronavirus and having a baseline level of crp below 150 mg/l
EP4359402A1 (en) * 2021-06-25 2024-05-01 Theravance Biopharma R&D IP, LLC Imidazolo indazole compounds as jak inhibitors
WO2023215478A1 (en) * 2022-05-05 2023-11-09 Theravance Biopharma R&D Ip, Llc Nezulcitinib for delivery by nebulized oral inhalation
WO2023230236A1 (en) 2022-05-26 2023-11-30 Theravance Biopharma R&D Ip, Llc Process for preparing jak inhibitors and intermediates thereof

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
EP1648455A4 (en) 2003-07-23 2009-03-04 Exelixis Inc MODULATORS OF ALK PROTEIN (ANAPLASTIC LYMPHOMA KINASE) AND METHODS OF USE
US20050090529A1 (en) 2003-07-31 2005-04-28 Pfizer Inc 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
US7884109B2 (en) 2005-04-05 2011-02-08 Wyeth Llc Purine and imidazopyridine derivatives for immunosuppression
US8648069B2 (en) 2007-06-08 2014-02-11 Abbvie Inc. 5-substituted indazoles as kinase inhibitors
JP2010111624A (ja) 2008-11-06 2010-05-20 Shionogi & Co Ltd Ｔｔｋ阻害作用を有するインダゾール誘導体
EP2414340A1 (en) 2009-04-03 2012-02-08 Dainippon Sumitomo Pharma Co., Ltd. Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
PL3001903T3 (pl) 2009-12-21 2018-03-30 Samumed, Llc 1H-pirazolo[3,4-b]pirydyny i ich zastosowania terapeutyczne
US8575336B2 (en) 2011-07-27 2013-11-05 Pfizer Limited Indazoles
EP3318565B1 (en) 2013-12-05 2021-04-14 Pfizer Inc. Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides
TN2016000503A1 (en) 2014-05-14 2018-04-04 Pfizer Pyrazolopyridines and pyrazolopyrimidines
WO2016026078A1 (en) 2014-08-19 2016-02-25 Changzhou Jiekai Pharmatech Co., Ltd. Heterocyclic compounds as erk inhibitors
KR101663277B1 (ko) 2015-03-30 2016-10-06 주식회사 녹십자 TNIK, IKKε 및 TBK1 억제제로서의 피라졸계 유도체 및 이를 포함하는 약학적 조성물
KR20180073687A (ko) * 2015-11-03 2018-07-02 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 호흡기 질환의 치료를 위한 jak 키나제 저해제 화합물
WO2017077288A1 (en) 2015-11-03 2017-05-11 Topivert Pharma Limited 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors
CA3037243A1 (en) 2015-11-03 2017-05-11 Topivert Pharma Limited 4,5,6,7-tetrahydro-1 h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors
US20180258546A1 (en) 2017-03-09 2018-09-13 Lam Research Corporation Electroplating apparatus and methods utilizing independent control of impinging electrolyte
EA037748B1 (ru) 2017-03-09 2021-05-18 ТЕРЕВАНС БАЙОФАРМА Ар энд Ди АйПи, ЭлЭлСи Конденсированные имидазо-пиперидиновые ингибиторы jak
CA3059785A1 (en) 2017-05-01 2018-11-08 Theravance Biopharma R&D Ip, Llc Methods of treatment using a jak inhibitor compound
EP3619208B1 (en) 2017-05-01 2023-06-07 Theravance Biopharma R&D IP, LLC Crystalline forms of a jak inhibitor compound
AR111495A1 (es) 2017-05-01 2019-07-17 Theravance Biopharma R&D Ip Llc Compuestos de imidazo-piperidina fusionada como inhibidores de jak
SG11202101751XA (en) 2018-09-04 2021-03-30 Theravance Biopharma R&D Ip Llc 5 to 7 membered heterocyclic amides as jak inhibitors
KR20210056381A (ko) * 2018-09-04 2021-05-18 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 Jak 억제제로서 디메틸 아미노 아제티딘 아마이드
TWI808250B (zh) 2018-09-04 2023-07-11 美商施萬生物製藥研發 Ip有限責任公司 用於製備jak抑制劑之方法及其中間體
JP2022506111A (ja) 2018-10-29 2022-01-17 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー Ｊａｋ阻害剤としての２－アザビシクロヘキサン化合物
PE20212069A1 (es) 2019-02-25 2021-10-26 Henan Medinno Pharmaceutical Tech Co Ltd Compuesto inhibidor de jak y uso del mismo
US11406640B2 (en) 2019-03-05 2022-08-09 Incyte Corporation JAK1 pathway inhibitors for the treatment of chronic lung allograft dysfunction
CN112279848A (zh) 2019-07-25 2021-01-29 四川海思科制药有限公司 一种泛JAKs抑制剂及其用途
TW202144343A (zh) * 2020-03-02 2021-12-01 美商施萬生物製藥研發 Ip有限責任公司 Jak抑制劑化合物之結晶水合物
WO2021226637A1 (en) * 2020-05-08 2021-11-11 Theravance Biopharma R&D Ip, Llc Method of treating a patient infected with a coronavirus with nezulcitinib
US20230021647A1 (en) * 2021-06-21 2023-01-26 Theravance Biopharma R&D Ip, Llc Method of treating a patient infected with a coronavirus and having a baseline level of crp below 150 mg/l

Also Published As

Publication number Publication date
IL281146B1 (en) 2023-08-01
US11634419B2 (en) 2023-04-25
US20210155620A1 (en) 2021-05-27
SG11202101734RA (en) 2021-03-30
IL281146B2 (en) 2023-12-01
JP7324836B2 (ja) 2023-08-10
CN112739697A (zh) 2021-04-30
MA53229A (fr) 2022-05-11
CO2021002977A2 (es) 2021-05-31
EA202190681A1 (ru) 2021-05-28
BR112021004052A2 (pt) 2021-05-25
AU2019336167A1 (en) 2021-03-11
KR20210056381A (ko) 2021-05-18
WO2020051105A1 (en) 2020-03-12
CN112739697B (zh) 2023-10-20
CL2021000514A1 (es) 2021-07-23
JP2021535177A (ja) 2021-12-16
US20200071323A1 (en) 2020-03-05
EP3837258A1 (en) 2021-06-23
EP3837258B1 (en) 2024-04-24
TW202024073A (zh) 2020-07-01
JP2022172299A (ja) 2022-11-15
US20230322774A1 (en) 2023-10-12
IL281146A (en) 2021-04-29
US10947229B2 (en) 2021-03-16
TWI791886B (zh) 2023-02-11
AR116115A1 (es) 2021-03-31

Similar Documents

Publication Publication Date Title
MX2021002521A (es) Dimetilaminoazetidinaminas como inhibidores de jak.
PH12019501985A1 (en) Fused imidazo-piperidine jak inhibitors
PH12018500828A1 (en) Jak kinase inhibitor compounds for treatment of respiratory disease
PH12021550324A1 (en) 5 to 7 membered heterocyclic amides as jak inhibitors
MX2022002938A (es) Compuestos inhibidores de la proteína arginina n-metil transferasa 5 (prmt5) cooperativos para metiltioadenosina (mta).
PH12019502264A1 (en) Fused imidazo-piperidine jak inhibitors compound
MD4800C1 (ro) Compuşi de aminopirimidinil ca inhibitori de JAK
MX2021004582A (es) Compuesto 2-azabiciclo hexano inhibidor de jak.
SG10201811384TA (en) Mnk inhibitors and methods related thereto
EA201891229A1 (ru) Eif4a-ингибирующие соединения и связанные с ними способы
MX2018013191A (es) Compuestos de pirimidina como inhibidores de la quinasa jak.
PH12019500569A1 (en) Blood-brain barrier-penetrant dopamine-b-hydroxylase inhibitors
TN2018000372A1 (en) Tetrahydropyrimidodiazepine and tetrahydropyridodiazepine compounds for treating pain and pain related conditions.
MX2021012501A (es) Inhibidores de complejo represivo polycomb 2 (prc2).
SA519401322B1 (ar) مركبات أريل كربوكساميد غير متجانسة كمثطبات لكيناز بروتين سيرين/ ثريونين متداخل مع المستقبل 2
MX2021006619A (es) Inhibidores de la tirosina quinasa, composiciones y sus metodos.
EA201692260A1 (ru) Соединения 1,3,4-тиадиазола и их применение в лечении рака
MX2020001531A (es) Nuevos compuestos hetorociclicos como inhibidores de cdk8/19.
PH12019500198A1 (en) Compounds and compositions and uses thereof
PH12017501668A1 (en) Bace1 inhibitors
PH12020500542A1 (en) Dopamine-b-hydroxylase inhibitors
MX2019014436A (es) Derivados de piridoquinazolina eficaces como inhibidores de proteina quinasa.
EA201792265A1 (ru) Способы лечения сердечно-сосудистых заболеваний
EA201991746A1 (ru) Производные пиразола в качестве ингибиторов бромодомена